Adaptive Biotechnologies Net Worth
Adaptive Biotechnologies Net Worth Breakdown | ADPT |
Adaptive Biotechnologies Net Worth Analysis
Adaptive Biotechnologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Adaptive Biotechnologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Adaptive Biotechnologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Adaptive Biotechnologies' net worth analysis. One common approach is to calculate Adaptive Biotechnologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Adaptive Biotechnologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Adaptive Biotechnologies' net worth. This approach calculates the present value of Adaptive Biotechnologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Adaptive Biotechnologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Adaptive Biotechnologies' net worth. This involves comparing Adaptive Biotechnologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Adaptive Biotechnologies' net worth relative to its peers.
Enterprise Value |
|
To determine if Adaptive Biotechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adaptive Biotechnologies' net worth research are outlined below:
| Adaptive Biotechnologies is way too risky over 90 days horizon | |
| Adaptive Biotechnologies appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 178.96 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 101.44 M. | |
| Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Adaptive Biotechnologies Corporation Rose on Solid Results |
Adaptive Biotechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adaptive Biotechnologies Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adaptive Biotechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Adaptive Biotechnologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adaptive Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptive Biotechnologies Corp backward and forwards among themselves. Adaptive Biotechnologies' institutional investor refers to the entity that pools money to purchase Adaptive Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aristotle Atlantic Partners, Llc | 2025-03-31 | 2.9 M | Geode Capital Management, Llc | 2025-03-31 | 2.8 M | State Street Corp | 2025-03-31 | 2.7 M | Massachusetts Financial Services Company | 2025-03-31 | 2.3 M | Driehaus Capital Management Llc | 2025-03-31 | 2.2 M | Blue Water Life Science Advisors, Llc | 2025-03-31 | 2.1 M | Iron Triangle Partners Lp | 2025-03-31 | 2.1 M | Goldman Sachs Group Inc | 2025-03-31 | 2 M | Victory Capital Management Inc. | 2025-03-31 | 1.8 M | Viking Global Investors Lp | 2025-03-31 | 30 M | Rubric Capital Management Lp | 2025-03-31 | 13.1 M |
Follow Adaptive Biotechnologies' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.6 B.Market Cap |
|
Project Adaptive Biotechnologies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.79) | (0.75) |
When accessing Adaptive Biotechnologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Adaptive Biotechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adaptive Biotechnologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Adaptive Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adaptive Biotechnologies Corp. Check Adaptive Biotechnologies' Beneish M Score to see the likelihood of Adaptive Biotechnologies' management manipulating its earnings.
Evaluate Adaptive Biotechnologies' management efficiency
Adaptive Biotechnologies has return on total asset (ROA) of (0.1505) % which means that it has lost $0.1505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6103) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.4 in 2025. Return On Capital Employed is likely to drop to -0.39 in 2025. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 265.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 87.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.38 | 2.04 | |
| Tangible Book Value Per Share | 0.54 | 0.52 | |
| Enterprise Value Over EBITDA | (7.18) | (7.54) | |
| Price Book Value Ratio | 4.35 | 4.57 | |
| Enterprise Value Multiple | (7.18) | (7.54) | |
| Price Fair Value | 4.35 | 4.57 | |
| Enterprise Value | 1 B | 952.5 M |
Effective leadership at Adaptive Biotechnologies drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 7.8783 | Revenue | Quarterly Revenue Growth 0.252 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptive Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptive Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptive Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adaptive Biotechnologies Corporate Filings
| 9th of July 2025 Other Reports | ViewVerify | |
8K | 12th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of May 2025 Other Reports | ViewVerify | |
F4 | 19th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Adaptive Biotechnologies Earnings per Share Projection vs Actual
Adaptive Biotechnologies Corporate Management
| Stacy JD | General VP | Profile | |
| Stacy Taylor | General VP | Profile | |
| Yi Zhou | Chief Officer | Profile | |
| Tycho Peterson | Chief Officer | Profile | |
| Kyle Piskel | Principal Officer | Profile | |
| Susan Bobulsky | Chief MRD | Profile |
Already Invested in Adaptive Biotechnologies Corp?
The danger of trading Adaptive Biotechnologies Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptive Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptive Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptive Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.